主动监测与远程患者监测指导重度无症状主动脉瓣狭窄瓣膜干预时机:APRAISE-AS pilot 随机对照试验结果
APRAISE-AS 是一项 12 个月、开放标签、两臂平行组随机对照预试验,在两家三级心脏中心纳入 38 例(共筛查 66 例)≥18 岁重度无症状主动脉瓣狭窄患者,1:1 随机分配至标准治疗或标准治疗加 APRAISE-AS 干预。主要目的是检验试验方案、评估干预可接受性并为全规模试验确定结局指标与样本量。结果显示远程监测可安全实施,患者对每周症状评估、每两周起立行走测试和每月 KCCQ 生活质量评估的依从率分别为 81%、91% 和 93%,但试验未招募到目标样本量。
要点
- 远程监测(症状追踪、衰弱评估、生活质量评分)在重度无症状 AS 患者中可安全实施且依从性高。
- 症状和 KCCQ 评分较基线变化可触发临床复核和转诊评估瓣膜置换。
- 该预试验未招募到目标样本量,需全规模试验进一步验证。
核心结论
- 对重度无症状主动脉瓣狭窄患者进行远程监测在临床实践中可安全实施,且数字化的临床路径为临床医生和患者所接受。
研究设计与样本
- 12 个月开放标签、两臂平行组随机对照预试验,在两家三级心脏中心开展。
- 共筛查 66 例,38 例≥18 岁重度无症状主动脉瓣狭窄患者按 1:1 随机分配至标准治疗(n=19)或标准治疗加 APRAISE-AS 干预(n=19)。
- 主要目的为检验试验方案、评估 APRAISE-AS 干预的可接受性,并为全规模随机对照试验确定最合适的结局指标和样本量。
主要发现
- 每周症状评估依从率为 81%,每两周起立行走测试依从率为 91%,每月使用堪萨斯城心肌病问卷(KCCQ)的健康相关生活质量评估依从率为 93%。
- 临床复核和转诊评估瓣膜置换由症状和 KCCQ 评分较基线的变化触发。
- 预试验未招募到目标样本量。
临床怎么用
- 可采用包含症状追踪、衰弱评估和生活质量评分的远程监测方案对重度无症状主动脉瓣狭窄患者进行主动监测。
- 以症状和 KCCQ 评分较基线变化作为触发临床复核和转诊评估瓣膜置换的指标。
局限性
- 预试验未招募到目标样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The insidious nature of aortic stenosis (AS) combined with the advanced age of the affected population results in underreporting of symptoms and underestimation of impact on functional capacity and quality of life. Although guidelines recommend early valve replacement in severe asymptomatic AS when coupled with adverse prognostic features, capacity within healthcare systems may limit translation into clinical practice. The use of remote monitoring and proactive surveillance to inform clinical management of heart valve disease is an underexplored area. APRAISE-AS evaluated the utility of remote monitoring to pre-empt/detect a change in clinical status (incorporating a symptom tracker, frailty assessment and quality of life score) to inform patient management. METHODS: 12-month open-label, two-arm, parallel group randomised controlled pilot trial conducted in two tertiary cardiac centres. 38/66 participants (≥18 years) with asymptomatic severe AS were randomly assigned (1:1) to standard care or the APRAISE-AS intervention in addition to standard care. The primary aim of the study was to (1) test the trial protocol, (2) determine acceptability of the APRAISE-AS intervention and (3) inform the most appropriate outcome measure(s) and sample size for a full-scale randomised controlled trial. RESULTS: 38 participants were assigned to standard care (n=19) or to standard care plus the APRAISE-AS intervention (n=19). Adherence rates were high: 81% for the weekly symptom assessments, 91% for the fortnightly timed up and go tests and 93% for the monthly health-related quality of life assessments using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Clinical review and onward referral for valve replacement were triggered by a change from baseline in symptoms and KCCQ scores. CONCLUSION: Remote monitoring of severe asymptomatic AS can be safely delivered in practice. Although the pilot did not recruit to target, a digitally enabled clinical pathway to optimise the management of asymptomatic severe AS is acceptable to clinicians and patients. TRIAL REGISTRATION NUMBER: ISRCTN19413194.
引用
- Khan N, Steeds RP, Mehta S, et al. Evaluating the use of proactive surveillance and remote patient monitoring to guide the timing of valve intervention in patients with severe asymptomatic aortic stenosis (APRAISE-AS): results of a pilot randomised controlled trial. Heart. 2026. PMID: 42642075. doi:10.1136/heartjnl-2026-327782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。